Overview

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Status:
NOT_YET_RECRUITING

Trial end date:
2029-11-30

Target enrollment:

Participant gender:

Summary

This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).

Phase:

PHASE1

Details

Lead Sponsor:

Daiichi Sankyo

Collaborator:

Bayer

Treatments:

darolutamide